As Of September 30, 2024 Autonomix Medical Had Cash Of $5.2M
As Of September 30, 2024 Autonomix Medical Had Cash Of $5.2M
Research and development expense was $1.2 million for the three months ended September 30, 2024 compared to $0.5 million for the same period in 2023. The increase in research and development expenses during the current quarter was mainly attributed to our clinical trial and product development costs.Summary of Financial Results for Three and Six Months Ended September 30, 2024
截至2024年9月30日的三个月和六个月的财务业绩摘要
For the three months ended September 30, 2024 and 2023, the Company incurred net losses of $2.8 million and $6.0 million, respectively.
在截至2024年9月30日和2023年9月30日的三个月中，该公司的净亏损分别为280万美元和600万美元。
General and administrative expense was $1.7 million for the three months ended September 30, 2024 compared to $0.8 million for the same period in 2023. This $0.9 million increase was driven primarily by increases in officer and employee compensation and benefits of $0.4 million, as we expanded our management team, stock-based compensation of $0.2 million, insurance expense of $0.1 million, franchise tax of $0.1 million, and other expenses of $0.1 million.
截至2024年9月30日的三个月，一般和管理费用为170万美元，而2023年同期为80万美元。这90万美元的增长主要是由管理团队扩大后高管和员工薪酬和福利增加了40万美元，股票薪酬增加了20万美元，保险费用为10万美元，特许经营税增加了10万美元，其他支出为10万美元。
Research and development expense was $1.2 million for the three months ended September 30, 2024 compared to $0.5 million for the same period in 2023. The increase in research and development expenses during the current quarter was mainly attributed to our clinical trial and product development costs.
截至2024年9月30日的三个月，研发费用为120万美元，而2023年同期为50万美元。本季度研发费用的增加主要归因于我们的临床试验和产品开发成本。
For the six months ended September 30, 2024 and 2023, the Company incurred net losses of $5.5 million and $6.9 million, respectively.
在截至2024年9月30日和2023年9月30日的六个月中，该公司的净亏损分别为550万美元和690万美元。
General and administrative expense was $3.5 million for the six months ended September 30, 2024 compared to $1.3 million for the same period in 2023. This $2.2 million increase was driven primarily by increases in officer and employee compensation and benefits of $1.0 million, as we expanded our management team, stock-based compensation of $0.6 million, legal and professional fees of $0.2 million, insurance expense of $0.2 million, franchise tax of $0.2 million, and board of directors compensation of $0.1 million, offset by a decrease in advertising expense of $0.1 million.
截至2024年9月30日的六个月中，一般和管理费用为350万美元，而2023年同期为130万美元。220万澳元的增长主要是由管理团队扩大后高管和员工薪酬和福利增加了100万美元，股票薪酬增加了60万美元，法律和专业费用20万美元，保险费用20万美元，特许经营税20万美元，董事会薪酬增加10万美元，被广告支出减少的10万美元所抵消。
Research and development expense was $2.1 million for the six months ended September 30, 2024 compared to $0.8 million for the same period in 2023. The increase in research and development expenses during the current year was mainly attributed to our clinical trial and product development costs.
截至2024年9月30日的六个月中，研发费用为210万美元，而2023年同期为80万美元。本年度研发费用的增加主要归因于我们的临床试验和产品开发成本。
As of September 30, 2024 the Company had cash of $5.2 million.
截至2024年9月30日，该公司的现金为520万美元。
